PROLLENIUM® Names Erick Brenner as Chief Executive Officer

RICHMOND HILL, Ontario--(BUSINESS WIRE)-- PROLLENIUM® Medical Technologies, a privately held medical aesthetics company, has appointed Erick Brenner as Chief Executive Officer, effective immediately. Brenner succeeds Walter Geiger, who has served as Interim CEO since April 2025, and will return to his role as Operating Partner at ARCHIMED, PROLLENIUM®’s majority shareholder.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126198897/en/

CEO of Prollenium Erick Brenner

Brenner most recently served as President of Galderma U.S., where he oversaw a $1.8 billion portfolio across injectable aesthetics, dermatologic skincare, and therapeutic dermatology. He brings more than 25 years of experience spanning pharmaceuticals, medical aesthetics, and consumer skincare, including senior leadership roles tied to major product launches, portfolio integrations, and Galderma’s recent initial public offering.

During Geiger’s tenure as Interim CEO, PROLLENIUM® advanced its science-led product strategy, strengthened its operational platform, and continued to scale its vertically integrated manufacturing capabilities in North America. Geiger joined the company during a transition period and is credited with helping position the business for its next phase of growth.

“PROLLENIUM® has benefited from strong operational leadership over the past year, and we are grateful to Walter for his stewardship during a critical period,” said Justin Bateman, Chair of the Board of Advisors. “Erick brings deep industry experience and a proven ability to scale global aesthetics platforms, which aligns well with the company’s long-term growth ambitions.”

Brenner said PROLLENIUM®’s differentiated operating model and focus on science-driven innovation were key factors in his decision to join the company.

“PROLLENIUM® has built a compelling platform by combining research and development, manufacturing, and commercial execution under one roof,” Brenner said. “I look forward to working with the team to continue expanding the company’s global presence while maintaining a strong focus on quality, safety, and clinical performance.”

For more information on PROLLENIUM®, please visit www.prollenium.com.

About PROLLENIUM®

Founded in 2002, PROLLENIUM® is a science-first innovator in facial aesthetics and regenerative skin technologies. PROLLENIUM® is one of the select few manufacturers to have received FDA approval for its state-of-the-art facilities and combines advanced research and development, high-quality manufacturing, and deep expertise in medical aesthetics. Aesthetic professionals trust PROLLENIUM® brands in over 70 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260126198897/en/

Media
Stuart Martin
213-235-8581
[email protected]

Source: Prollenium

You May Also Be Interested In

• U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• U.S. Public Sector Moves Toward Zero Trust Security
• Nu Mexico Receives Authorization to Begin Operations as a Bank